Table 1 Studies on transphyseal ACL reconstruction
Nr | First author, year | No. of patients | Age of patients (years) | Study design | MINORS | Femoral drilling technique | Graft | Tanner stage | Mean follow up (years) | Re-rupture (%) | Contralateral ACL rupture (%) | Growth abnormalities with need for treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Shelbourne, 2004 | 16 | 14.8 | Retrospective | 9 | TT | BTB | 3–4 | 3.4 | 1 (6.3%) | 2 (12.5%) | 0 |
2 | McIntosh, 2006 | 18 | 13.8 | Retrospective | 8 | TT | HT | NR | 3.4 (2–9.3) | 2 (11.1%) | NR | 1 |
3 | Liddle, 2008 | 17 | 12.1 | Retrospective | 7 | TT | HT | NR | 4.4 | 1 (5.9%) | NR | 0 |
4 | Cohen, 2009 | 26 | 13.3 | Retrospective | 7 | TT | HT | NR | 4.5 | 3 (11.5%) | NR | 0 |
5 | Streich et al. 2010 | 16 | 11 | Retrospective | 9 | TT | HT | 1–2 | 5.8 | 0 (0) | NR | 0 |
6 | Mauch, 2011 | 49 | 13 | Retrospective | 10 | TT | QT | NR | 5 | 5 (10.2%) | 5 (10.2%) | 1 |
7 | Nikolaou, 2011 | 94 | 13.7 | Retrospective | 10 | TT | HT | NR | 3.2 (2–5) | 4 (4.3%) | NR | 0 |
8 | Courvoisier, 2011 | 37 | 14 | Retrospective | 6 | TT | HT | NR | 2 | 5 (13.5%) | NR | 0 |
9 | Hui, 2012 | 16 | 12 | Prospective | 13 | MP | HT from living donor | NR | 2.1 (1.8–2.8) | 0 (0) | 0 (0) | 0 |
10 | Redler, 2012 | 18 | 14.2 | Retrospective | 9 | TT | HT | NR | 3.6 (2–7.2) | 0 (0) | 3 (16.6%) | 0 |
11 | Memeo 2012 | 10 | 14.4 | Retrospective | 7 | TT | BTB | 3 | 15 | 1 (10.0%) | NR | 0 |
12 | Kumar, 2013 | 32 | 11.3 | Prospective | 9 | TT | HT | 1–3 | 6 (4–10.8) | 1 (3.1%) | 1 (3.1%) | 0 |
13 | Kohl, 2014 | 15 | 12.8 | Prospective | 9 | TT | QT | 2–4 | 4 (2–8) | 0 (0) | NR | 0 |
14 | Calvo et al. 2015 | 27 | 13 | Retrospective | 10 | TT | HT | 2–4 | 10.6 (10–13) | 5 (18.5%) | NR | 0 |
15 | Fauno, 2016 | 39 | 11.7 | Prospective | 11 | TT | HT | NR | 5.6. ± 2.8 | 1 (2.6%) | NR | 0 |
16 | Siebold, 2016 | 35 | 13.6 | Retrospective | 9 | MP | HT | NR | 3.4 + -1.3 | 9 (26.7%) | NR | 0 |
17 | Placella,2016 | 24 | 13.2 ( | Retrospective | 9 | All inside | HT | 1–5 | 8 | 0 (0) | NR | 0 |
18 | Pennoc, 2019 | 90 | 14.8 | Retrospective | 12 | Outside in | QT (27), HT (53) | NR | 2.8 | 13 (14.4%) QT: 1 (3.7%) HT: 12 (22.6%) | 10 (11.1%) QT: 5 (18.5%) HT: 5 (9.4%) | 0 |
19 | Astur, 2019 | 52 | 13.6 | Retrospective | 8 | TT | HT | NR | 7.4 | 18 (34.6%) | NR | 0 |
20 | Gosh, 2020 | 100 | 14 (8–16) | Prospective | 12 | MP | HT from living donor | 1–5 | 2 | 12 (12.0%) | 9 (9.0%) | 0 |
21 | Hanssen, 2022 | 193 | 12.5 (7–15) | Prospective | 11 | TT | HT | NR | 6.9 (5–9) | 24 (12.4%) | 23 (11.9%) | NR |
22 | Kilkenny, 2022 | 86 | 12–15 | Retrospective | 10 | MP | HT (59) BTB (27) | NR | 2 | 6 (7.0%) HT: 6 (10.2) BTB: 0 (0) | 5 (5.8%) HT: 3 (5.1%) BTB: 2 (7.4%) | NR |
Total | 1010 | 111 (11.0%) | 58 (9.7%) | 2 (0.2%) |